List of Excipients in API dapagliflozin and saxagliptin
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing dapagliflozin and saxagliptin
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | ANHYDROUS LACTOSE | |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | CELLULOSE, MICROCRYSTALLINE | |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | CROSCARMELLOSE SODIUM | |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | FERROUS OXIDE | |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | MAGNESIUM STEARATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing dapagliflozin and saxagliptin
Detailed excipient profiles for dapagliflozin and saxagliptin
Excipient focus: ANHYDROUS LACTOSE
dapagliflozin and saxagliptin drug variants containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
dapagliflozin and saxagliptin drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
dapagliflozin and saxagliptin drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
dapagliflozin and saxagliptin drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
dapagliflozin and saxagliptin drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERROUS OXIDE
dapagliflozin and saxagliptin drug variants containing FERROUS OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing FERROUS OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
dapagliflozin and saxagliptin drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
dapagliflozin and saxagliptin drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
dapagliflozin and saxagliptin drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
dapagliflozin and saxagliptin drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
dapagliflozin and saxagliptin drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
dapagliflozin and saxagliptin drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
dapagliflozin and saxagliptin drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
Excipient focus: STEARIC ACID
dapagliflozin and saxagliptin drug variants containing STEARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing STEARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
dapagliflozin and saxagliptin drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
dapagliflozin and saxagliptin drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| Novadoz Pharmaceuticals LLC | dapagliflozin and saxagliptin | 72205-438 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links